Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the "CAPS Registry"
- PMID: 35085802
- DOI: 10.1016/j.autrev.2022.103055
Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the "CAPS Registry"
Abstract
Objectives: To describe the real-world experience of eculizumab use in patients with catastrophic antiphospholipid syndrome (CAPS) according to the information provided by the "CAPS Registry".
Methods: We analyzed the demographic, clinical and immunological data from all the patients included in the "CAPS Registry" treated with eculizumab and described the indications for eculizumab administration, dose, outcome, use of prophylactic vaccines and adverse effects.
Results: The "CAPS Registry" currently includes 584 patients from whom 39 (6.7%) were treated with eculizumab (it was used as a rescue therapy in 30 cases while in 6 cases it was used as first line therapy). Mean age of eculizumab treated patients was 39 years (SD = 14.6), 72% were female, 77% had a primary APS and 79% had a precipitating factor before the CAPS event. Thrombocytopenia was present in 28 (72%) cases and features of microangiopathic hemolytic anemia were present in 15 (38.5%). Twenty-nine (74.4%) patients recovered from the episode of CAPS (four showed only partial remission). Symptoms worsened in 9 patients, from whom 5 finally died despite the treatment. There was only one relapse after a median follow up of 10.7 months. The most common treatment regimen was 900 mg weekly for four weeks and 1200 mg fortnightly.
Conclusion: According to the real-world experience provided by the "CAPS Registry", eculizumab can be considered in some patients with CAPS refractory to previous therapies, especially if they present with features of complement-mediated thrombotic microangiopathy.
Keywords: Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Complement; Eculizumab; Intravenous immunoglobulins; Plasma exchange.
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Catastrophic antiphospholipid syndrome: an update.Panminerva Med. 2017 Sep;59(3):254-268. doi: 10.23736/S0031-0808.17.03324-9. Epub 2017 May 8. Panminerva Med. 2017. PMID: 28488841 Review.
-
Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome.J Clin Rheumatol. 2015 Sep;21(6):311-3. doi: 10.1097/RHU.0000000000000290. J Clin Rheumatol. 2015. PMID: 26267719
-
Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".J Autoimmun. 2009 May-Jun;32(3-4):240-5. doi: 10.1016/j.jaut.2009.02.008. Epub 2009 Mar 26. J Autoimmun. 2009. PMID: 19324520
-
Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab.Arthritis Rheum. 2012 Aug;64(8):2719-23. doi: 10.1002/art.34440. Arthritis Rheum. 2012. PMID: 22354668
-
Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.Semin Arthritis Rheum. 2019 Aug;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005. Epub 2018 Dec 4. Semin Arthritis Rheum. 2019. PMID: 30598332 Review.
Cited by
-
Antiphospholipid Patients Admitted in the Intensive Care Unit: What Must The Rheumatologist Know?Curr Rheumatol Rep. 2024 Jul;26(7):269-277. doi: 10.1007/s11926-024-01148-7. Epub 2024 Apr 23. Curr Rheumatol Rep. 2024. PMID: 38652403 Review.
-
Cutting-Edge Techniques and Drugs for the Treatment of Pulmonary Embolism: Current Knowledge and Future Perspectives.J Clin Med. 2024 Mar 28;13(7):1952. doi: 10.3390/jcm13071952. J Clin Med. 2024. PMID: 38610717 Free PMC article. Review.
-
Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.Antibodies (Basel). 2024 Mar 12;13(1):21. doi: 10.3390/antib13010021. Antibodies (Basel). 2024. PMID: 38534211 Free PMC article. Review.
-
Eculizumab therapy and complement regulation in a case of resistant catastrophic antiphospholipid syndrome.BMJ Case Rep. 2024 Mar 5;17(3):e254449. doi: 10.1136/bcr-2022-254449. BMJ Case Rep. 2024. PMID: 38442982
-
Four clinical and biological phenotypes in antiphospholipid syndrome: a cluster analysis of 174 patients with antinuclear antibody tests.Front Immunol. 2024 Feb 19;15:1361062. doi: 10.3389/fimmu.2024.1361062. eCollection 2024. Front Immunol. 2024. PMID: 38440737 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous